#Taiwan #Frankfurt #Traditional Chinese Medicine #CPHI Frankfurt

Taiwan's Traditional Chinese Medicine Pavilion at CPHI Frankfurt 2025

Taiwan made a significant splash at the CPHI Frankfurt 2025, held from October 28 to 30, with its Traditional Chinese Medicine (TCM) Pavilion drawing considerable global interest. The event attracted pharmaceutical professionals and distributors eager for collaboration in innovative herbal solutions based on evidence and OEM/ODM alliances.

The Pavilion, organized by the Department of Chinese Medicine and Pharmacy (DCMP) under Taiwan's Ministry of Health and Welfare, and implemented by the Taiwan Institute of Economic Research (TIER), showcases Taiwan's comprehensive approach to TCM. This approach harmonizes a rich clinical heritage with modern scientific validation and a robust regulatory framework.

On the first day of the event, the Pavilion was privileged to participate in the CPHI Newsbeat Stage, presenting a compelling narrative directly to leading international industry media. TIER made a brief announcement about how Taiwan's TCM model is being redefined through science and innovation. A highlight of the event was a live interview with Raman Sehgal, host of the prominent life sciences podcast, Molecule to Market, which attracted around ten media outlets.

During the interview session, attention was drawn to NRICM101, a formulation developed during the COVID-19 pandemic. This formulation exemplifies Taiwan's evidence-based methodology, supported by multiple peer-reviewed studies that have demonstrated its efficacy in reducing severe complications associated with the virus.

The Taiwanese Pavilion featured five leading companies: Chuang Song Zong, Li Kang Biotech, Timing Pharmaceutical, Taiwan Three Mast, and Grape King Bio. These companies exemplify Taiwan's dynamic TCM industry, characterized by excellence in research, innovative product development, and the production of GMP-certified products for global markets.

At the core of the Pavilion’s scientific focus is the National Research Institute of Chinese Medicine (NRICM), which presented formulas NRICM101 and NRICM102. These multi-target pharmacological formulations inhibit viral activity, reduce inflammation, and prevent severe outcomes from COVID-19. Users of NRICM102 have exhibited a 74% lower mortality rate, highlighting the global potential of Taiwan's scientific model of Traditional Chinese Medicine.

Dr. Yi-Chang Su, the director of the DCMP and NRICM, emphasized, "The integration of TCM and modern science in Taiwan continues to gain global recognition. We hope to forge partnerships that extend reliable, evidence-based TCM to wider markets."

Throughout the exhibition, delegates from the Pavilion are expected to engage with pharmaceutical companies, regulatory experts, and industry advocacy organizations from Europe and America to explore potential collaborations aimed at promoting global health through Taiwan's evidence-based TCM model. As Taiwan continues to position itself at the forefront of Traditional Chinese Medicine on the international stage, events like CPHI Frankfurt 2025 are vital in showcasing its achievements and fostering international partnerships.

The emerging narratives from the Pavilion not only reflect Taiwan’s commitment to health innovation but also its active role in the global discourse on integrative medicine.